-

Mevion Medical Systems Appoints Curt Kienast as Chief Operating Officer

LITTLETON, Mass.--(BUSINESS WIRE)--Mevion Medical Systems, the leader in compact proton therapy, today announced the appointment of Curt Kienast to chief operating officer of the organization, effective immediately. In this role, Kienast is responsible for leading the company’s end to end processes, scaling development, and amplifying operational excellence.

“I am very proud to announce the promotion of Curt to chief operating officer,” said Tina Yu, chief executive officer of Mevion Medical Systems. “Curt is a 13-year Mevion veteran, and his passion has proved to be vital to our organization, and as we evolve, he will be a leader who can propel our strengths and our expansion.”

Proton therapy is a more precise therapeutic radiation to the tumor and less damaging to nearby organs and is becoming a favored tool among top centers around the world. Mevion provides the most compact and precise proton systems available today and has been selected by leading clinical centers in the U.S., Europe, and China.

Kienast was previously vice president of global service. He has held many cross-functional roles during his tenure, including leadership roles in quality assurance, engineering, and service. Kienast’s innovative approaches to customer service and lean manufacturing have been instrumental in the company’s continued growth and success.

“I am honored and excited for the opportunity to lead Mevion’s team in a greater capacity,” said Curt Kienast. “Mevion has secured a distinctive position in the global market, and my goal is to ensure we maintain our competitive edge, our culture of customer service, and build on our teams’ unified focus to drive us into the future.”

About Mevion Medical Systems

Mevion Medical Systems, Inc. is the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients. Mevion is based in Littleton, Massachusetts, with a presence in Europe and Asia. For more information, please visit www.mevion.com.

Follow us on Twitter: @MevionMedical
Connect with us on LinkedIn: Mevion Medical Systems
Like Us on Facebook: MevionMedical

Contacts

Melanie Benton
Mevion Medical Systems
Mbenton@mevion.com 1-978-540-1551

More News From Mevion Medical Systems, Inc.

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Selects MEVION S250-FIT™ for Southern Italy’s First Proton Therapy Center

LITTLETON, Mass.--(BUSINESS WIRE)--Mevion Medical Systems, the global leader in compact proton therapy, today announced that it has been selected to deliver the MEVION S250-FIT Proton Therapy System™ to Istituto Nazionale Tumori IRCCS Fondazione G. Pascale in Naples. The award, made following a competitive European tender, will establish the first proton therapy center in Southern Italy, significantly expanding access to advanced radiation therapy for patients across the region and reducing the...

Mevion to Bring MEVION S250-FIT™ Proton Therapy System to Multidisciplinary Care Setting

BOSTON--(BUSINESS WIRE)--Mevion Medical Systems, a leader in compact proton therapy solutions, today announced that Dana-Farber Cancer Institute will install the MEVION S250-FIT Proton Therapy System™ at its Longwood Medical Area campus. The installation will integrate proton therapy directly into Dana-Farber's multidisciplinary care environment, including pediatric care delivered through the Dana-Farber/Boston Children's Cancer and Blood Disorders Center. “Proton therapy is a critical tool in...

Mevion Introduces the First Proton Therapy System Designed for a LINAC Vault at ESTRO 2026

LITTLETON, Mass.--(BUSINESS WIRE)--Proton therapy is entering the LINAC vault. At ESTRO 2026, Mevion Medical Systems will introduce the MEVION S250-FIT Proton Therapy System to the European radiation oncology community, the first proton therapy system designed for installation in a standard radiation therapy vault. Now both U.S. FDA-cleared and CE-marked under Regulation (EU) 2017/745, the S250-FIT creates a new pathway for cancer centers to bring proton therapy into existing LINAC-based treatm...
Back to Newsroom